d Pooled analysis of Bauersachs et al21 (EINSTEIN-DVT) and Buller et al26 (EINSTEIN-PE) performed by Prins et al.183 Bibliography: Prins et al183 TABLE 4 ] Summary of Findings: Apixaban vs LMWH and VKA for Acute and Long-Term Treatment of VTEa,b Outcomes No. of Participants (Studies) Quality of the Evidence (GRADE) Relative Effect Anticipated Absolute Effects Risk with LMWH and VKA Risk Difference with Apixaban (95% CI) All-cause mortality Moderatec because of imprecision (from 9 fewer to 4 more) Recurrent VTE 5,244 Moderatec because of imprecision (from 11 fewer to 5 more) Major bleeding 5,365 High (from 8 fewer to 15 fewer) The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). AMPLIFY Apixiban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy; PE pulmonary embolism. See Table 1 legend for expansion of other abbreviations and GRADE Working Group grades of evidence. a Apixaban 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 mo. b Subcutaneous enoxaparin, followed by warfarin. c CI includes values suggesting no effect and values suggesting either bene t or harm. Bibliography: Agnelli et al25 (AMPLIFY) 324 Evidence-Based Medicine [ 1 4 9 # 2 C H E S T F E B R U A R Y 2 0 1 6 ] a preference for either an NOAC or VKA. In the absence of direct comparisons between NOACs, and no convincing indirect evidence that one NOAC is superior to another, we do not have a preference for one NOAC over another NOAC. 